Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $16.57M rose 113.6% year over year, behind the +141.5% change in trailing-twelve-month research & development. Sequentially, it rose 15.9% from the prior quarter. Over 3 fiscal years it compounded at +89.7% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +113.6% toward the trailing-twelve-month pace of +141.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 48.94M USD
- Year-over-year change
- +181.8%
- 3-year CAGR
- +89.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.94M | +181.8% |
| FY2024 | 2024-12-31 | 17.36M | +287.6% |
| FY2023 | 2023-12-31 | 4.48M | -37.5% |
| FY2022 | 2022-12-31 | 7.17M | — |
Research & Development vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 research & development of $57.75M is the 7th highest of the 11 companies compared; the peer median is $63.62M.
- Its year-over-year change of +141.5% is the highest of 11, against a peer median of +0.4%.
- Over three fiscal years its annual growth of +89.7% compares with a peer median of +0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $62.37M | -24.6% | -10.1% | 27721.8% | |
| LTM Mar 2026 | $57.75M | +141.5% | +89.7% | — | |
| LTM Mar 2026 | $55.01M | +74.4% | +17.0% | 93235.6% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
| LTM Mar 2026 | $40.3M | -12.6% | +4.1% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M | +72.6% | +29.4% | — |
| Peer median (excluding AARD) | $63.62M | +0.4% | +0.8% | 550.2% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 7.17M | 4.48M | 17.36M | 48.94M |
| Selling, General & Admin | 2.7M | 2.17M | 5.31M | 13.79M |
| Operating Expenses | 11.36M | 7.42M | 22.79M | 62.73M |
| Depreciation & Amortization | 110K | 97K | 16K | 36K |
| EBITDA | (10.76M) | (6.56M) | (22.65M) | (57.56M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (11.36M) | (7.42M) | (22.79M) | (62.73M) |
| Operating Margin | — | — | — | — |
| Interest Income | 120K | 1.42M | 2.41M | 5.14M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.2M) | 207K | 2.2M | 5.13M |
| Income Before Tax | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.63) | (0.34) | (0.95) | (2.64) |
| EPS (Diluted) | (0.63) | (0.34) | (0.95) | (2.64) |
| Weighted Avg Shares | 21.38M | 21.38M | 21.7M | 21.82M |
| Weighted Avg Shares (Diluted) | 21.38M | 21.38M | 21.7M | 21.82M |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.